Hsp90: A novel target for the disruption of multiple signaling cascades

被引:89
作者
Bishop, Stephanie C.
Burlison, Joseph A.
Blagg, Brian S. J. [1 ]
机构
[1] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA
[2] Univ Kansas, Dept Med Chem, Lawrence, KS 66045 USA
关键词
Hsp90; heat shock protein; cancer; inhibitor; molecular chaperone; protein folding; geldanamycin; radicicol;
D O I
10.2174/156800907780809778
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The 90 kDa heat shock proteins (Hsp90) are proving to be an excellent target for thc development of novel anticancer agents designed to selectively block the growth and proliferation of tumor cells, Since Hsp90 is a molecular chaperone and is responsible for folding numerous oncogenic proteins, its inhibition represents a novel approach toward the simultaneous disruption of multiple signaling cascades. This review summarizes recent literature implicating Hsp90 as a key facilitator for the maturation of proteins represented in all six hallmarks of cancer: 1) growth signal self-sufficiency, 2) anti-growth signal insensitivity, 3) evasion of apoptosis, 4) unlimited replicative potential, 5) metastasis and tissue invasion, and 6) sustained angiogenesis. Also described are recent advances towards the development of novel Hsp90 inhibitors via, structure-based drug design that have contributed to the number of compounds undergoing clinical development.
引用
收藏
页码:369 / 388
页数:20
相关论文
共 136 条
  • [1] Akalin A, 2001, CANCER RES, V61, P4791
  • [2] Targeting of Rab GTPases to cellular membranes
    Ali, BR
    Seabra, MC
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 2005, 33 : 652 - 656
  • [3] Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90 - Evidence that coumarin antibiotics disrupt Hsp90 dimerization
    Allan, RK
    Mok, D
    Ward, BK
    Ratajczak, T
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (11) : 7161 - 7171
  • [4] Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones
    Arlander, SJH
    Felts, SJ
    Wagner, JM
    Stensgard, B
    Toft, DO
    Karnitz, LM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (05) : 2989 - 2998
  • [5] ATRASH B, 2004, TETRAHEDRON LETT, P2237
  • [6] High-throughput screening for Hsp90 ATPase inhibitors
    Avila, C
    Hadden, MK
    Ma, ZQ
    Kornilayev, BA
    Ye, QZ
    Blagg, BSJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (11) : 3005 - 3008
  • [7] Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
    Bagatell, R
    Beliakoff, J
    David, CL
    Marron, MT
    Whitesell, L
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (02) : 179 - 188
  • [8] Bagatell R, 2004, MOL CANCER THER, V3, P1021
  • [9] Phase I pharmacokinetic and pharmacodynarnic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies
    Banerji, U
    O'Donnell, A
    Scurr, M
    Pacey, S
    Stapleton, S
    Asad, Y
    Simmons, L
    Maloney, A
    Raynaud, F
    Campbell, M
    Walton, M
    Lakhani, S
    Kaye, S
    Workman, P
    Judson, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4152 - 4161
  • [10] The topoisomerase II-Hsp90 complex: A new chemotherapeutic target?
    Barker, CR
    Hamlett, J
    Pennington, SR
    Burrows, F
    Lundgren, K
    Lough, R
    Watson, AJM
    Jenkins, JR
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (11) : 2685 - 2693